Drugs / GR1603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06015230 | Mar 2022 → Jun 2028 expected | systemic lupus erythematosus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR1603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06015230 ↗ |
| Action | Inhibit | “which can block IFNAR binding to type I interferons” NCT06015230 ↗ |
| Modality | Monoclonal antibody | “GR1603 injection is a monoclonal antibody targeting IFNAR1” NCT06015230 ↗ |
| Route | Intravenous | “intravenously administered GR1603” NCT06015230 ↗ |
| Target | IFNAR1 | “GR1603 injection is a monoclonal antibody targeting IFNAR1” NCT06015230 ↗ |